Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Cipla
Julphar
Harvard Business School
QuintilesIMS
Daiichi Sankyo
Medtronic
Fish and Richardson
Mallinckrodt
US Army

Generated: October 19, 2017

DrugPatentWatch Database Preview

Kastle Theraps Llc Company Profile

« Back to Dashboard

What is the competitive landscape for KASTLE THERAPS LLC, and when can generic versions of KASTLE THERAPS LLC drugs launch?

KASTLE THERAPS LLC has one approved drug.

There are six US patents protecting KASTLE THERAPS LLC drugs.

There are five hundred and fifty-nine patent family members on KASTLE THERAPS LLC drugs in twenty-six countries.

Summary for Applicant: Kastle Theraps Llc

International Patents:559
US Patents:6
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Kastle Theraps Llc
KYNAMRO
mipomersen sodium
SOLUTION;SUBCUTANEOUS203568-001Jan 29, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Kastle Theraps Llc
KYNAMRO
mipomersen sodium
SOLUTION;SUBCUTANEOUS203568-001Jan 29, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Kastle Theraps Llc
KYNAMRO
mipomersen sodium
SOLUTION;SUBCUTANEOUS203568-001Jan 29, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Kastle Theraps Llc
KYNAMRO
mipomersen sodium
SOLUTION;SUBCUTANEOUS203568-001Jan 29, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Kastle Theraps Llc
KYNAMRO
mipomersen sodium
SOLUTION;SUBCUTANEOUS203568-001Jan 29, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Kastle Theraps Llc
KYNAMRO
mipomersen sodium
SOLUTION;SUBCUTANEOUS203568-001Jan 29, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Kastle Theraps Llc
KYNAMRO
mipomersen sodium
SOLUTION;SUBCUTANEOUS203568-001Jan 29, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Kastle Theraps Llc
KYNAMRO
mipomersen sodium
SOLUTION;SUBCUTANEOUS203568-001Jan 29, 2013RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Kastle Theraps Llc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Kastle Theraps Llc
KYNAMRO
mipomersen sodium
SOLUTION;SUBCUTANEOUS203568-001Jan 29, 2013► Subscribe► Subscribe
Kastle Theraps Llc
KYNAMRO
mipomersen sodium
SOLUTION;SUBCUTANEOUS203568-001Jan 29, 2013► Subscribe► Subscribe
Kastle Theraps Llc
KYNAMRO
mipomersen sodium
SOLUTION;SUBCUTANEOUS203568-001Jan 29, 2013► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Kastle Theraps Llc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,803,930Antisense modulation of apolipoprotein B-expression► Subscribe
5,760,202 Process for the synthesis of 2'-O-substituted pyrimidines► Subscribe
RE44760Antisense modulation of apolipoprotein B-expression► Subscribe
6,222,025 Process for the synthesis of 2'-O-substituted pyrimidines and oligomeric compounds therefrom► Subscribe
6,642,367 Process for the synthesis of 2'-O-substituted pyrimidines and oligomeric compounds therefrom► Subscribe
7,888,324Antisense modulation of apolipoprotein B expression► Subscribe
5,861,493 Process for the synthesis of 2'-O-substituted pyrimidines► Subscribe
8,735,364Antisense modulation of apolipoprotein B expression► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Kastle Theraps Llc Drugs

Country Document Number Estimated Expiration
European Patent Office1044987► Subscribe
Japan2732544► Subscribe
Japan5342493► Subscribe
Japan3535519► Subscribe
Australia2003302042► Subscribe
Japan2879973► Subscribe
Australia2003290966► Subscribe
Austria204879► Subscribe
Canada2126691► Subscribe
Australia4167499► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Daiichi Sankyo
Colorcon
Novartis
US Army
Fish and Richardson
Express Scripts
Chubb
Cantor Fitzgerald
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot